Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Cash & Equivalents (2019 - 2026)

C4 Therapeutics has reported Cash & Equivalents over the past 8 years, most recently at $61.3 million for Q1 2026.

  • For Q1 2026, Cash & Equivalents rose 19.46% year-over-year to $61.3 million; the TTM value through Mar 2026 reached $61.3 million, up 19.46%, while the annual FY2025 figure was $74.6 million, 34.42% up from the prior year.
  • Cash & Equivalents for Q1 2026 was $61.3 million at C4 Therapeutics, down from $74.6 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $126.6 million in Q4 2023 and troughed at $29.8 million in Q4 2022.
  • A 5-year average of $62.7 million and a median of $58.8 million in 2025 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: plummeted 79.62% in 2022 and later surged 325.46% in 2023.
  • Year by year, Cash & Equivalents stood at $29.8 million in 2022, then surged by 325.46% to $126.6 million in 2023, then tumbled by 56.16% to $55.5 million in 2024, then soared by 34.42% to $74.6 million in 2025, then decreased by 17.87% to $61.3 million in 2026.
  • Business Quant data shows Cash & Equivalents for CCCC at $61.3 million in Q1 2026, $74.6 million in Q4 2025, and $58.8 million in Q3 2025.